INO-4800

DB15693InvestigationalVaccines

INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that... Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs.

Mechanism: Pharmacologically active on Spike glycoprotein
Curator reviewed
Also known as: INO-4800 DNA Coronavirus Vaccine
Code names: INO-4800

Resolves to

Compound

UNII5Y0I0UU2IT

Targets

P0DTC2S

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with INO-4800, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account